EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy

Anna S Chesnokova iD, Alisa B Ageenko iD, Natalia S Vasileva iD, Arina A Byvakina iD, Anna A Nushtaeva iD, Anastasia A Leonteva iD, Yulya I Savinovskaya, Galina V Kochneva iD, Vladimir A Richter, Elena V Kuligina iD, Dmitriy V Semenov iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Anna S Chesnokova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia. Hauptthemen laut MEDLINE: Glioma, Oncolytic Virotherapy, Programmed Cell Death 1 Receptor, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Russian state funded project for ICBFM SB RAS, Russian state-funded.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both oncolytic virotherapy and immune checkpoint blockade are being actively explored as immunotherapy treatments for glioblastoma, one of the most lethal malignancies. Nevertheless, the antitumor molecular mechanisms of these therapies remain poorly understood, particularly whether they induce overlapping or distinct transcriptional programs. No comprehensive transcriptome-wide characterization and direct comparison of the responses induced by VV-GMCSF-Lact and anti-PD-1 therapy in glioma have been reported. To address this question, we performed whole-transcriptome profiling of GL261 tumors from immunocompetent C57BL/6 mice treated with VV-GMCSF-Lact, anti-PD-1 antibodies, or their combination. We analyzed therapy-associated changes in gene expression, signaling pathways, and tumor composition. Our findings indicate that anti-PD-1 and combination treatment led to distinctive activation of interferon-gamma response, JAK/STAT signaling, and TNF-alpha/NF-kB pathways. In contrast, VV-GMCSF-Lact preferentially activated T, B, and natural killer T cell-associated programs and reduced the relative abundance of malignant cells. Notably, combination therapy was associated with unique molecular patterns, including induction of monocyte and granulocyte chemotaxis-associated genes, downregulation of PP2A-regulated signaling, and suppression of Rap1-related pathways. This suggests that VV-GMCSF-Lact and anti-PD-1 therapy induce transcriptionally distinct, yet complementary, immune reprogramming and support further evaluation of their combination for glioma immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaOncolytic VirotherapyProgrammed Cell Death 1 ReceptorGranulocyte-Macrophage Colony-Stimulating FactorTranscriptomeImmune Checkpoint InhibitorsBrain NeoplasmsAnimalsMiceGene Expression ProfilingMice, Inbred C57BLCell Line, TumorGene Expression Regulation, NeoplasticSignal TransductionImmunotherapy

Stichwörter der Autor:innen

C57BL/6 miceGL261 glioma mouse cell lineVV-GMCSF-Lactanti-PD-1 therapycancer virotherapyimmune checkpoint inhibitors

Substanzen

Programmed Cell Death 1 ReceptorGranulocyte-Macrophage Colony-Stimulating FactorImmune Checkpoint InhibitorsPdcd1 protein, mouse

Autor:innen und Institutionen

  • Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Lavrentyev Avenue 8, Novosibirsk 630090, Russia.
  • Research Center for Genetics and Life Sciences, Sirius University of Science and Technology, Krasnodar Region, Sirius (Federal Territory of Sirius), Sochi 354340, Russia.
  • State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo 630559, Russia.
  • Oncostar LLC, Inzhenernaya Street 23, Novosibirsk 630090, Russia.

ORCID-Profile: Anna S Chesnokova, Alisa B Ageenko, Natalia S Vasileva, Arina A Byvakina, Anna A Nushtaeva, Anastasia A Leonteva, Galina V Kochneva, Elena V Kuligina, Dmitriy V Semenov

Förderung

  • Russian Science Foundation
  • Russian state funded project for ICBFM SB RAS
  • Russian state-funded

Zitieren

APA

Chesnokova, A. S., Ageenko, A. B., Vasileva, N. S., Byvakina, A. A., Nushtaeva, A. A., Leonteva, A. A., Savinovskaya, Y. I., Kochneva, G. V., Richter, V. A., Kuligina, E. V., & Semenov, D. V. (2026). Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188078

Vancouver

Chesnokova AS, Ageenko AB, Vasileva NS, Byvakina AA, Nushtaeva AA, Leonteva AA, et al. Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188078

BibTeX
@article{Chesnokova2026,
  author = {Chesnokova, Anna S and Ageenko, Alisa B and Vasileva, Natalia S and Byvakina, Arina A and Nushtaeva, Anna A and Leonteva, Anastasia A and Savinovskaya, Yulya I and Kochneva, Galina V and Richter, Vladimir A and Kuligina, Elena V and Semenov, Dmitriy V},
  title = {Whole-Transcriptome Profiling of Murine GL261 Glioma Reveals Signatures Consistent with Distinct Immune Reprogramming Induced by Oncolytic Virotherapy with VV-GMCSF-Lact and Anti-PD-1 Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188078}
}
Kostenlos starten →